Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9773258 | 0.79 | CA1 (0.35) | CA1CA2CA5ACA9 | |
| SCHEMBL30238802 | 0.76 | CA1 (0.37) | CA1CA2CA5ACA9ALDH1A1 | |
| SCHEMBL3533547 | 0.76 | CA1 (0.37) | CA1CA2CA5ACA9ALDH1A1 | |
| SCHEMBL14349291 | 0.72 | CYP2D6 (0.44) | ALDH1A1CYP2D6CYP1A2CYP3A4 | |
| SCHEMBL9935977 | 0.69 | CYP2A6 (0.32) | ALDH1A1CTSSCTSK | |
| SCHEMBL9686923 | 0.69 | CA2 (0.41) | CA1CA2CA5ACA9ALDH1A1 | |
| SCHEMBL30503531 | 0.68 | ALDH1A1 (0.50) | CA1CA2CA5ACA9ALDH1A1 | |
| SCHEMBL9275642 | 0.68 | ALDH1A1 (0.43) | CA1CA2CA5ACA9ALDH1A1 | |
| SCHEMBL5080120 | 0.68 | ALDH1A1 (0.43) | CA1CA2CA5ACA9ALDH1A1 | |
| SCHEMBL28655742 | 0.68 | ALDH1A1 (0.43) | CA1CA2CA5ACA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288581-B2 | Process for the preparation of functionalised benzocyclobutenes, and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2012-10-16 | — | — | US | disclosed |
| US-20120116112-A1 | PROCESS FOR THE PREPARATION OF FUNCTIONALISED BENZOCYCLOBUTENES, AND APPLICATION IN THE SYNTHESIS OF IVABRADINE AND ADDITION SALTS THEREOF WITH A PHARMACEUTICALLY ACCEPTABLE ACID | LES LABORATOIRES SERVIER (FR) | 2012-05-10 | — | — | US | disclosed |
| US-8110701-B2 | Process for the preparation of functionalised benzocyclobutenes, and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2012-02-07 | — | — | US | disclosed |
| WO-2010007253-A2 | NOVEL METHOD FOR PREPARING FUNCTIONALIZED BENZOCYCLOBUTENES, AND USE IN THE SYNTHESIS OF IVABRADINE AND OF ADDITION SALTS THEREOF WITH A PHARMACEUTICALLY ACCEPTABLE ACID | LES LABORATOIRES SERVIER (FR) | 2010-01-21 | — | — | WO | disclosed |
| US-20100016580-A1 | Process for the preparation of functionalised benzocyclobutenes, and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2010-01-21 | — | — | US | disclosed |
| EP-2145871-A1 | New method for preparing functionalised benzocyclobutenes and its application to the synthesis of ivabradine and its addition salts with a pharmaceutically acceptable acid. | Les Laboratoires Servier (FR) | 2010-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016580-A1 | Process for the preparation of functionalised benzocyclobutenes, and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | BDKRB2, HRH2, C1R | L3MBTL1 3517/4885CA1 1101/4885CA2 412/4885 |
| US-20120116112-A1 | PROCESS FOR THE PREPARATION OF FUNCTIONALISED BENZOCYCLOBUTENES, AND APPLICATION IN THE SYNTHESIS OF IVABRADINE AND ADDITION SALTS THEREOF WITH A PHARMACEUTICALLY ACCEPTABLE ACID | CYP4F2, CYP2B6, CYP4F8 | L3MBTL1 4619/4885CA1 2099/4885CA2 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.